Aprovel har desuden været genstand for to store undersøgelser med henblik på behandling af nyresygdom hos i alt 2 326 patienter med type 2 diabetes.
For the treatment of kidney disease, Aprovel was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.